Abstract
A case of acute myelogenous leukemia with a t(8;21) translocation relapsed 5 months after allogeneic bone marrow transplantation (allo-BMT). After chemotherapy-induced hematologic remission, the patient received donor lymphocyte infusions (DLI); 4.9 × 108/kg T cells were infused. After DLI, she achieved molecular CR for the first time after allo-BMT, which lasted for 40 months. However, she suffered from grade III acute GVHD of the skin and the liver. Hepatic GVHD was sustained and resulted in fatal outcome. The case demonstrates that DLI is a double-edged sword. Further study is necessary before DLI can be considered to be a beneficial therapy for acute leukemia. Bone Marrow Transplantation (2000) 26, 809–810.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kumar L . Leukemia: management of relapse after allogeneic bone marrow transplantation J Clin Oncol 1994 12: 1710–1717
Kishi K, Takahashi S, Gondo H et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes Bone Marrow Transplant 1997 19: 461–466
Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of GVL responses from GVHD Blood 1995 86: 1261–1268
Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients Blood 1995 86: 2041–2050
Kantarjian HM, O’Brien S, Anderlini P, Talpaz M . Treatment of chronic myelogenous leukemia: current status and investigational options Blood 1996 87: 3069–3081
Collins RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 1997 15: 433–444
Buzyn-Veil A, Belanger C, Audat F et al. Sustained complete cytologic and molecular remission induced by donor leukocyte infusions alone in an acute myeloblastic leukemia in relapse after bone marrow transplantation Br J Haematol 1996 92: 423–425
Fores R, Diez-Martin JL, Briz M et al. Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation Bone Marrow Transplant 1996 17: 439–441
Alessandro EP, Bernasconi P, Caldera D et al. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation Bone Marrow Transplant 1999 23: 607–612
Azuno Y, Kaneko T, Nishimura M et al. Donor leukocyte transfusions and discontinuation of immunosuppressants to achieve an initial remission after allogeneic bone marrow transplantation in a patient with primary refractory acute leukemia Bone Marrow Transplant 1996 18: 257–259
Acknowledgements
We thank Prof Shintaro Shiobara for encouraging us to publish our work and to Ms Kuniko Numata for her assistance in preparing the manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Imoto, S., Murayama, T., Gomyo, H. et al. Long-term molecular remission induced by donor lymphocyte infusions for recurrent acute myeloblastic leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 26, 809–810 (2000). https://doi.org/10.1038/sj.bmt.1702602
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702602
Keywords
This article is cited by
-
Monitoring minimal residual disease in AML: the right time for real time
Annals of Hematology (2003)